Effect of Epinephrine/ Phenylephrine for Preventing the Postreperfusion Syndrome During Reperfusion in Liver Transplantation

This study has been completed.
Information provided by (Responsible Party):
Chul-Woo Jung, Seoul National University Hospital
ClinicalTrials.gov Identifier:
First received: March 2, 2010
Last updated: May 1, 2012
Last verified: May 2012
Postreperfusion syndrome (PRS) is a relatively common phenomenon in patients undergoing liver transplantation which is characterized by an acute drop in blood pressure immediately after the prefusion is restored to the transplanted liver. We hypothesized that PRS would be prevented when phenylephrine or epinephrine is administered immediately prior to reperfusion in liver transplantation.

Condition Intervention
Hypotension After Reperfusion in Liver Transplantation
Drug: phenylephrine
Drug: epinephrine
Drug: placebo control

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Effect of Preventive Medicine on the Postreperfusion Syndrome

Resource links provided by NLM:

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • Occurrence of Postreperfusion Syndrome (PRS) [ Time Frame: immediately after reperfusion ] [ Designated as safety issue: No ]
    the number of patients who showed PRS (hypotension defined as < 30% of baseline mean arterial pressure [MAP] lasting over 1 min immediately after reperfusion of liver graft) was divided by the total number of patients enrolled for each group

Enrollment: 96
Study Start Date: April 2010
Study Completion Date: October 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: phenylephrine
100 mcg of phenylephrine is administered at the time of reperfusion
Drug: phenylephrine
100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
Experimental: epinephrine
10 mcg of epinephrine is administered iv at the time of reperfusion
Drug: epinephrine
10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
Placebo Comparator: control
10 ml of normal saline is administered at the time of reperfusion
Drug: placebo control
10ml of normal saline is administered at the time of reperfusion


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- adults scheduled to undergo liver transplantation

Exclusion Criteria:

- pediatric liver transplantation

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01080625

Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
Principal Investigator: Chul-Woo Jung, MD Seoul National University Hospital
  More Information

No publications provided by Seoul National University Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Chul-Woo Jung, Assistant professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT01080625     History of Changes
Other Study ID Numbers: CWJung_phen_epi_liver TPL 
Study First Received: March 2, 2010
Results First Received: February 13, 2012
Last Updated: May 1, 2012
Health Authority: Korea: Institutional Review Board

Keywords provided by Seoul National University Hospital:
postreperfusion syndrome
liver transplantation

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases
Epinephryl borate
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-1 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic beta-Agonists
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Cardiotonic Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Nasal Decongestants
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Respiratory System Agents
Therapeutic Uses
Vasoconstrictor Agents

ClinicalTrials.gov processed this record on February 08, 2016